To maximize the efficacy of TACE, prognostic factors, including AFP level, tumor size, liver function reserve, and the presence of portal vein thrombosis [3, 24, 25], were extensively investigated to identify patients who were most likely to benefit from TACE, and these factors are consistent with the findings of our study. This evidence concerns the gene AFP and neoplasm.